港股早評:恒指高開0.18% 生物醫藥股、黃金股普升 半導體股走低
不懼關税大棒,港股春節假期迎來大升行情,尤其是科技龍頭表現十分強勢。今日三大指數開盤升跌不一,恒指升0.18%,國指升0.11%,恒生科技指數微跌0.03%。盤面上,大型科技股多數繼續走高,美團升2.65%,百度升超2%,小米升1%有望再刷歷史新高,騰訊飄紅;香港1月初進入流感季節,生物醫藥股升幅居前,艾美疫苗升超8%,君實生物升近3%;現貨金價升破2840再創歷史記錄,黃金股集體上升,山東黃金升2.5%,招金礦業升近2%,核電股、光伏股、風電股、紙業股、手機概念股齊升。另一方面,春節期間大升的軟件類股、半導體股走低,金山雲跌超7%,中芯國際跌超3%昨日創下歷史新高。(格隆匯)
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.